Objective: Total bilirubin (TB) of >7 mg/dl is an accepted definition of postoperative hepatic insufficiency (PHI) given its association with the occurrence of complications and mortality after hepatectomy. The aim of this study was to identify a surrogate marker for PHI early in the postoperative course.
Introduction
Improvements in patient selection, perioperative management, cross-sectional imaging and surgical techniques in liver resection have led to increases in both the indications for hepatectomy and the number of operations performed. Once as high as 20%, mortality rates after major hepatectomy have recently been reported to be as low as 1.3%. [1] [2] [3] [4] [5] Although it is not a frequent occurrence, postoperative hepatic insufficiency (PHI) is a devastating complication that remains a major cause of post-hepatectomy mortality. 3, 6, 7 In the last decade, in excess of 50 studies have sought to define post-hepatectomy liver failure. 2, [8] [9] [10] [11] Many authors incorporate postoperative serum bilirubin values and the international normalized ratio (INR) in their definitions; others consider clinical conditions, such as hepatic encephalopathy or ascites, and still others use a combination of the two. 2, 12, 13 The timing of the measurement of these variables in the postoperative period is also inconsistent: some studies measure at 4, 5 and 7 days postoperatively, whereas others describe merely the presence of a particular variable at any time-point. For example, the '50-50 criteria' utilize both bilirubin level and INR on postoperative day 5 (PoD 5) as predictors of post-hepatectomy mortality. By contrast, Hyder et al. proposed a comprehensive algorithm for predicting PHI after hepatectomy. 4 One of the most commonly accepted and simplest definitions of PHI is a peak total serum bilirubin of >7 mg/dl in the postoperative period. 2 Regardless of which definition of PHI is applied, all of them are limited by the fact that in most patients PHI is not identified until late in the postoperative course. An early predictor of PHI and adverse outcomes would be helpful to identify at-risk patients. The aim of this study was to identify a simple and early postoperative predictor of subsequent hepatic insufficiency and other adverse outcomes, including complications and early mortality, after major hepatectomy.
Materials and methods
Institutional review board approval for this study was obtained and the protocol was conducted in accordance with the Health Insurance Portability and Accountability Act of 1996. All patients who underwent major hepatectomy, defined as the resection of three or more anatomical liver segments, between January 2000 and July 2012 were identified from a prospectively maintained, single-institution database. Patients who underwent biliary reconstruction and those for whom bilirubin data were inadequate were excluded from this study.
A complete review of medical records was performed. Basic demographic and clinicopathologic data were collected and recorded in the database, as were preoperative and postoperative relevant laboratory values, operative details and outcomes. Individual total bilirubin levels and INR were recorded on PoDs 1-5. When multiple values were available for a single 24-h period, the highest value was recorded as the value for that time period. Peak postoperative total bilirubin and INR for up to 30 days postoperatively were recorded.
The study objective was to identify a predictor of PHI early in the postoperative period. The primary outcome was PHI, specifically defined as a peak postoperative bilirubin level of >7 mg/dl and/or the presence of new ascites. 2, 14 Secondary outcomes included any complication, major complications defined as those of Clavien-Dindo Grades III-V, and 90-day all-cause mortality. 15 All demographic, clinicopathologic and operative data were assessed for significant relationships with PHI using the chisquared or Fisher's exact tests for categorical variables and Student's t-test or the Mann-Whitney U-test for continuous variables, as appropriate. Variables associated with PHI were identified on univariate analysis; those found to have a statistically significant association (P < 0.05) were included in a multivariate logistic regression to assess independent correlation. Receiver operating characteristic (ROC) curve analysis was performed to identify the total bilirubin level in the early postoperative period that was best associated with the subsequent development of PHI. Once this value was identified, univariate and multivariate models were constructed for each secondary endpoint. Finally, demographic and pre-and intraoperative clinicopathologic variables were analysed for their associations with the early postoperative bilirubin level that best predicted PHI. A P-value of < 0.05 was considered to indicate statistical significance.
Results
Of the 751 patients who underwent major hepatectomy at Emory University Hospital during 2000-2012, 144 (19.2%) patients underwent concomitant biliary reconstruction and were consequently excluded from this study. Of the remaining 607 patients, 535 (88.1%) had sufficient data on total bilirubin levels available for analysis. Demographic, clinicopathologic and perioperative data are summarized in Table 1 . The cohort included 443 patients (73.0%) with a diagnosis of cancer, of which the most common indication for operation was colorectal liver metastasis (n = 232, 52.4%). The mean ± standard deviation (SD) preoperative total bilirubin level was 0.7 ± 0.65 mg/dl. Sixty patients (11.2%) met the criteria for PHI. Postoperative complications occurred in 352 patients (65.8%) and major complications (Clavien-Dindo Grades III-V) occurred in 125 (23.4%). The 90-day mortality rate was 5.0% (n = 27) and the readmission rate was 17.4% (n = 93).
To identify an early postoperative indicator of PHI, an ROC curve was constructed ( Fig. 1 ) to ascertain the early postoperative bilirubin level best associated with PHI. Bilirubin levels for the first 3 days postoperatively were analysed and that for PoD 3 revealed the best fit curve [area under the curve (AUC): 0.85]. A PoD 3 bilirubin value of ≥3 mg/dl had the strongest association with the subsequent development of PHI, with sensitivity of 60% and specificity of 86%. The positive predictive value of PoD 3 bilirubin of ≥3 mg/dl for the development of PHI was 33.0% (34 of 103 patients), and the negative predictive value was 94.0% (406 of 432 patients).
On univariate analysis, several demographic and preoperative variables were found to be significantly associated with PHI, including older age, male gender, cancer diagnosis, low preoperative albumin, a preoperative Model for End-stage Liver Disease (MELD) score of ≥8, and a preoperative tissue diagnosis of cirrhosis. Perioperative variables that significantly increased the risk for progression to PHI were higher intraoperative estimated blood loss (EBL), requirement for intraoperative blood transfusion, fresh frozen plasma (FFP) transfusion before PoD 2, and a PoD 3 total bilirubin level of ≥3 mg/dl. Of all of these factors, only PoD 3 total bilirubin of ≥3 mg/dl demonstrated an independent association with PHI on multivariate analysis ( Table 2) .
On PoD 3, 432 patients showed a total bilirubin level of < 3 mg/dl and 103 showed a total bilirubin level of ≥3 mg/dl. Patients with a PoD 3 total bilirubin level of ≥3 mg/dl demonstrated a significantly increased risk for the occurrence of any complication (75.7% versus 53.9%; P < 0.001), a major PHI, postoperative hepatic insufficiency complication (45.6% versus 17.6%; P < 0.001), and 90-day mortality (15.5% versus 2.3%; P < 0.001) ( Fig. 2 ).
Univariate and multivariate logistic regression models were developed for each secondary outcome of any complication, major complications and 90-day mortality (Tables 3-5 ). Risk factors for any complication include American Society of Anesthesiologists (ASA) class ≥3 status, an FFP transfusion requirement on or before PoD 2, and PoD 3 total bilirubin of ≥3 mg/dl. Risk factors for the occurrence of a major complication include White European ethnicity, an FFP transfusion requirement on or before PoD 2, and PoD 3 total bilirubin of ≥3 mg/dl. Variables associated with increased risk for 90-day mortality include older age and PoD 3 total bilirubin of ≥3 mg/ dl. Importantly, only PoD 3 total bilirubin of ≥3 mg/dl was significantly associated on multivariate analysis with all three outcomes of any complication, a major complication and 90-day mortality.
Pre-and intraoperative factors were evaluated for their association with the development of a PoD 3 total bilirubin level of ≥3 mg/dl. Patients with PoD 3 bilirubin of ≥3 mg/dl were more likely to be male (57.3%; P = 0.001), have cancer (85.4%; P = 0.003), have a preoperative platelet count of < 150 000 (16.5%; P = 0.013), have a preoperative MELD score of ≥8 (33.7%; P = 0.007), have higher EBL (P = 0.008), and receive intraoperative blood transfusions (32.4%; P = 0.019). However, in a multivariate analysis model, none of the pre-or intraoperative factors emerged as predictive of a PoD 3 total bilirubin level of ≥3 mg/dl (Table 6 ). 
Discussion
The purpose of this study was to identify an early predictor of PHI. When PHI was defined as total serum bilirubin of >7 mg/dl and/or the formation of new ascites, PoD 3 bilirubin was predictive of subsequent PHI. Specifically, a PoD 3 bilirubin level of ≥3 mg/dl was associated with increased risk for PHI [hazard ratio (HR) = 7.78, 95% confidence interval (CI) 4.05-14.94; P < 0.001], as well as for postoperative complications (HR = 1.98, 95% CI 1.10-3.54; P = 0.022), major postoperative complications (HR = 3.18, 95% CI 1.90-5.32; P < 0.001) and 90-day mortality (HR = 8.11, 95% CI 3.00-21.92; P < 0.001). Analysis of the ROC curve revealed that PoD 3 bilirubin rendered the best fit curve for PHI, with an AUC of 0.85. The dichotomizing of patients according to bilirubin levels of < 3 mg/dl and ≥3 mg/dl provided sensitivity of 60% and specificity of 86%. When tested in a multivariate model with other factors associated with PHI, a PoD 3 bilirubin level of ≥3 mg/dl remained the only factor significantly associated with PHI (Tables 2-5 ).
The consistency of PoD 3 total bilirubin of ≥3 mg/dl as an early predictor of PHI was internally validated by determining its association with the secondary outcomes of any complication, a major complication and 90-day mortality. On multivariate regression analysis, a PoD 3 total bilirubin level of ≥3 mg/dl was the only perioperative factor to remain significantly associated with all three secondary outcomes (Tables 3-5 ). In an effort to identify at-risk patients even earlier in their treatment course, pre-and intraoperative factors were assessed for their associations with a PoD 3 total bilirubin level of ≥3 mg/ dl. Although several variables were associated with PoD 3 total bilirubin of ≥3 mg/dl, none of these associations persisted on multivariate analysis. Thus, although PoD 3 total bilirubin of ≥3 mg/dl is an early postoperative predictor that confers significant risk for morbidity and mortality, there were no pre-or intraoperative risk factors that allowed for the earlier identification of these patients.
The indications and selection criteria for performing major hepatectomy are continuing to expand. 3, 6, 16, 17 Even with existing techniques, such as volumetric measurements and portal vein embolization to optimize the future liver remnant, PHI remains a significant concern because it is associated with increased morbidity and mortality. Although numerous studies have attempted to produce a standard definition for PHI, there is no universally accepted classification. Furthermore, many of these current definitions are subject to retrospective analysis or latecourse recognition. A PoD 3 bilirubin level of ≥3 mg/dl identifies patients who are at significant risk for complications and 90-day mortality, as well as possibly serving as an early indicator of PHI.
There are several limitations to this study. One major limitation concerns the current lack of clinical treatment alternatives in the context of the early identification of risk for PHI. It is possible that as bridging treatments such as molecular adsorbent recirculating systems and plasma separation and filtration are developed for the injured liver, the early identification of these patients may become more clinically relevant and time-sensitive because a therapeutic option to improve liver function or support the body while the liver recuperates can be provided. [18] [19] [20] Other limitations include the retrospective method of analysis, which limits the interpretation of causality between predictors and outcomes and suggests only association. An additional limitation of the present study refers to the lack of standardized, specific clinical management protocols, such as for blood product transfusion, which were based on physician-specific clinical decision making. Finally, the future liver remnant, although an important consideration in patients with PHI, is not routinely calculated and thus could not be included in the analysis.
In this series of 535 patients submitted to major hepatectomy, a total bilirubin level of ≥3 mg/dl on PoD 3 was associated with the development of PHI, and increased risk for any postoperative complications, major postoperative complications and 90-day mortality. No preoperative risk factors correctly identified patients at risk for developing a total bilirubin level of ≥3 mg/dl on PoD 3. Although a PoD 3 total bilirubin level of ≥3 mg/dl may be an early-course predictor of PHI, continued research is necessary to identify preoperative predictors of and rescue treatments for PHI.
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